Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
35.18
USD
+3.05%
+8.38%
+57.97%
This article is reserved for members
Not a member ?
Free registration
Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss
02/05
MT
Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
02/05
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M
02/05
MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
02/05
CI
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating
16/02
MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
15/02
CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises
15/02
MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
15/02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
15/02
CI
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
10/01
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing
10/01
MT
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
08/01
CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints
03/01
MT
Agios' blood disorder drug meets goals of late-stage study
03/01
RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
03/01
CI
Transcript : Agios Pharmaceuticals, Inc. - Special Call
03/01
Transcript : Agios Pharmaceuticals, Inc. - Special Call
11/12
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition
10/12
CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
20/11
CI
Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $28 From $32, Maintains Neutral Rating
03/11
MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
02/11
CI
Transcript : Agios Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
02/11
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $7.5M
02/11
MT
Transcript : Agios Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM
12/23/12
Insider Sell: Agios Pharmaceuticals
22/23/22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
More about the company
Last Close Price
35.18
USD
Average target price
41.67
USD
Spread / Average Target
+18.44%
Consensus
1st Jan change
Capi.
+57.97% 2B +7.52% 113B +11.38% 106B +0.79% 22.27B -12.64% 22.22B -4.41% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**